Welcome to our dedicated news page for Imunon (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Imunon 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Imunon 's position in the market.
Rhea-AI Summary
IMUNON, Inc. (NASDAQ: IMNN) has received FDA clearance to start a Phase 1 clinical trial for IMNN-101, a DNA-based vaccine for COVID-19. The trial aims to evaluate safety, tolerability, antibody response, and durability in healthy adults. IMNN-101 is expected to offer superior immune protection compared to mRNA vaccines. The company plans to enroll 24 subjects across two U.S. sites to test three escalating doses against the Omicron XBB1.5 variant. IMUNON's PlaCCine platform shows promising results in non-human primates, with high immunogenicity, stability, and manufacturing advantages over other vaccine types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (NASDAQ: IMNN) has regained compliance with the Nasdaq minimum bid price requirement, ensuring its listing on the Nasdaq Capital Market. The company's common stock maintained a minimum closing bid price of $1.00 or more for 10 consecutive trading days, meeting the compliance rule. IMUNON's Executive Chairman highlighted the importance of this event and expressed confidence in the company's dual platform technologies. Additionally, the company is set to report topline results from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer and initiate a Phase 1 clinical study for a seasonal COVID-19 booster vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (IMNN) reports financial results for 2023 and updates on clinical development programs, highlighting positive outcomes with IMNN-001 in Phase 2 clinical trials for ovarian cancer and promising results with PlaCCine modality for next-generation vaccines. The company submitted an IND application for a seasonal COVID-19 booster vaccine and launched a new production facility. Management remains optimistic about the progress and potential partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.14%
Tags
Rhea-AI Summary
IMUNON, Inc. (IMNN) receives $1.3 million in non-dilutive funding through the sale of unused New Jersey net operating losses, strengthening its balance sheet. The funding aims to support the company's clinical development programs and shareholder focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (IMNN) to host conference call to discuss financial results and clinical development programs for 2023. Focus on DNA-mediated immunotherapy and next-generation vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.01%
Tags
-
Rhea-AI Summary
IMUNON, Inc. files IND application for Phase 1 study of IMNN-101 COVID-19 booster vaccine using DNA-based technology. The study aims to evaluate safety, durability, and immune response superiority over mRNA vaccines. Enrollment expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
Rhea-AI Summary
IMUNON, Inc. announces the resignation of Dr. Corinne Le Goff as President and CEO, with Executive Chairman Michael H. Tardugno assuming day-to-day operations. The company remains focused on key milestones for its drug-development programs, with upcoming Phase 1 studies and topline data releases expected. An active search for a new CEO is underway, and financial results for 2023 will be reported soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (IMNN) reports positive results from a murine study conducted by the Wistar Institute with their IMNN-101 vaccine against the SARS-CoV-2 variant XBB.1.5. The study showed immunogenicity and protective activity in mice, with higher T-cell responses compared to mRNA vaccines. IMNN-101 demonstrated stability at refrigerated temperatures for at least four weeks and elicited robust IgG and neutralizing antibody responses. The vaccine provided complete protection in mice challenged with live virus 21 days after the second vaccination. IMUNON's PlaCCine technology presents itself as a promising alternative to mRNA vaccines, with comparable or superior protection against SARS-CoV-2 and enhanced storage benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.33%
Tags
-
Rhea-AI Summary
IMUNON, Inc. announces a Phase 1/2 clinical trial with Memorial Sloan Kettering Cancer Center evaluating IMNN-001 in combination with bevacizumab for advanced ovarian cancer. The trial aims to detect minimal residual disease and improve progression-free survival, potentially revolutionizing ovarian cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.39%
Tags
Rhea-AI Summary
IMUNON, Inc. announces strong immunogenicity and protection with its PlaCCine DNA-based vaccine modality. The study published in the peer-reviewed journal Vaccine demonstrates the effectiveness of IMUNON's proprietary formulation against SARS-CoV-2 variants, highlighting stable DNA vaccine products, induction of neutralizing antibodies and cytotoxic T cells, and suppression of viral replication. IMUNON plans to file an IND application with the FDA and start a Phase 1/2 study soon, aiming to provide potent and durable immunity against COVID-19.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
Imunon, Inc.
Nasdaq:IMNN
IMNN Rankings
IMNN Stock Data
12.31M
9.37M
1.15%
4.47%
4.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
LAWRENCEVILLE
About IMNN
celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.